No Data
No Data
No Data
No Data
No Data
CervoMed Updates Stakeholders on Clinical and Financial Status
TipRanksApr 23 20:13
CervoMed Is Maintained at Buy by Canaccord Genuity
CervoMed Is Maintained at Buy by Canaccord Genuity
Dow JonesApr 8 19:48
Canadian Investment Banking Group: Maintaining the CervOmed (CRVO.US) rating, adjusted from buy to buy rating, and adjusted the target price from $50.00 to $65.00.
Canadian Investment Banking Group: Maintaining the CervOmed (CRVO.US) rating, adjusted from buy to buy rating, and adjusted the target price from $50.00 to $65.00.
Zhitong FinanceApr 8 19:40
Canaccord Genuity Maintains Buy on CervoMed, Raises Price Target to $65
Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed with a Buy and raises the price target from $50 to $65.
Analyst UpgradesApr 8 19:37
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)
TipRanksApr 8 19:30
CervoMed Shares Operational and Financial Insights Online
TipRanksApr 4 19:12
No Data
No Data